Dual‐Targeted Lipid Nanotherapeutic Boost for Chemo‐Immunotherapy of Cancer

• Published in: Advanced materials (Weinheim) Vol. 34; no. 13; pp. e2106350 - n/a
• Main Authors: Yong, Seok‐Beom, Ramishetti, Srinivas, Goldsmith, Meir, Diesendruck, Yael, Hazan‐Halevy, Inbal, Chatterjee, Sushmita, Somu Naidu, Gonna, Ezra, Assaf, Peer, Dan
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.04.2022
• Subjects: Cancer; cancer‐targeted therapy; Cell death; chemo‐immunotherapy; HO1‐targeted nanotherapeutics; Immunotherapy; ionizable lipid nanoparticle; Lipids; Lymphocytes; Materials science; Nanoparticles; targeted lipid nanoparticle; Tumors; targeted lipid nanoparticle; chemo-immunotherapy; ionizable lipid nanoparticle; cancer-targeted therapy; HO1-targeted nanotherapeutics
• ISSN: 0935-9648; 1521-4095
• DOI: 10.1002/adma.202106350

Chemo‐immunotherapy is a combination of “standard‐of‐care” chemotherapy with immunotherapy and it is considered the most advanced therapeutic modality for various types of cancers. However, many cancer patients still poorly respond to current regimen of chemo‐immunotherapy and suggest nanotherapeutics as a boosting agent. Recently, heme oxygenase‐1 (HO1) is shown to act as an immunotherapeutic molecule in tumor myeloid cells, in addition to general chemoresistance function in cancer cells suggesting that HO1‐targeted therapeutics can become a novel, optimal strategy for boosting chemo‐immunotherapy in the clinic. Currently the available HO1‐inhibitors demonstrate serious adverse effects in clinical use. Herein, tumor myeloid cell‐ and cancer cell‐dual targeted HO1‐inhibiting lipid nanotherapeutic boost (T‐iLNTB) is developed using RNAi‐loaded lipid nanoparticles. T‐iLNTB‐mediated HO1‐inhibition sensitizes cancer cells to “standard‐of‐care” chemotherapeutics by increasing immunogenic cell death, and directly reprograms tumor myeloid cells with distinguished phenotype. Furthermore, tumor myeloid cell reprogramming by T‐iLNTB induces CD8+ cytotoxic T cell recruitment, which drives “Cold‐to‐Hot” transition and correlates with improved responsiveness to immune checkpoint inhibitor in combination therapy. Finally, ex vivo study proves that HO1‐inhibition directly affects tumor macrophage differentiation. This study demonstrates the potential of T‐iLNTB as a novel therapeutic modality for boosting chemo‐immunotherapy. The phase III clinical trials of chemo‐immunotherapy suggest nanotherapeutics as a boosting agent. Here, dual‐targeted lipid nanotherapeutic boost (T‐iLNTB) is developed for chemo‐immunotherapy of cancer. T‐iLNTB boosts chemotherapeutic effect in cancer cells, increases an immunogenic cell death and reprograms tumor myeloid cells, consequently, recruits T cells and boosts responsiveness to immunotherapeutics. T‐iLNTB can become a novel therapeutic modality in cancer.